UNIVERSITY OF WASHINGTON

A case study from the NIH Pragmatic Trials Collaboratory describes an interim reassessment of sample size during an ongoing cluster randomized trial, FM-TIPS, which examines the effect of transcutaneous electrical nerve stimulation on movement-evoked pain in fibromyalgia patients.

The 'Innovations in Flow Cytometry & Extracellular Vesicles 2024' conference, hosted by ResearchAndMarkets.com, brings together researchers and industry participants to discuss the latest developments in EV/Exosomes fields. The event emphasizes technology development, particularly in flow cytometers, and features an extensive international perspective with speakers, poster presenters, sponsors, and exhibitors from the US, Europe, and Asia/Pacific. The conference includes co-located tracks on Lab-on-a-Chip, Microfluidics, and Organoids, offering extensive networking opportunities.

The 2024 Nobel Prize in Chemistry was awarded to Demis Hassabis, John Jumper, and David Baker for using machine learning to predict protein 3D shapes and design them from scratch, addressing a major biological challenge. This marks a significant shift, as the research originated from DeepMind, a tech company acquired by Google in 2014. The award highlights the blending of AI and biology, with AlphaFold2 predicting over 200 million protein structures, accelerating research in medicine and drug development.

Meiler lab awarded $46 million to develop a 'super-vaccine' against alphaviruses, leveraging computational techniques and a multidisciplinary team.

Bhagwat Prasad, PhD, joins Cincinnati Children’s as division director of Translational and Clinical Pharmacology in spring 2025, bringing expertise in drug safety for underrepresented populations. He aims to expand interdisciplinary networks and advance drug development, pediatric pharmacology, and education.

Cyrus Biotechnology congratulates David Baker, Demis Hassabis, and John Jumper for winning the Nobel Laureate Award in Chemistry for their protein structure prediction discoveries. Cyrus, co-founded by Baker, focuses on developing innovative therapeutics using AI to overcome challenges in protein drugs, such as immunogenicity. The company aims to bring an AI-optimized IdeS variant to first-in-human trials in 2026.

The 2024 Nobel Prize in Chemistry was awarded to three scientists for advancing protein understanding, paving the way for new research, including Stanford's work on custom proteins to fight severe COVID-19. Collaborations between David Baker and Stanford researchers led to designing miniproteins that block cytokine storms, potentially offering a new treatment approach.

Demis Hassabis and John Jumper won the 2023 Nobel Prize in Chemistry for their AlphaFold 2 AI model, which accurately predicts protein structures from DNA sequences, revolutionizing biological research and drug development.

Africa's high chronic kidney disease prevalence lacks sufficient genetic data, highlighting the need for diverse genome datasets to improve disease understanding and treatment efficacy. The underrepresentation of African genomes in studies has worsened, affecting the accuracy of polygenic risk scores and drug development. Initiatives like NIH's All of Us and the Nigerian 100K Genome Project aim to bridge this gap, emphasizing the importance of equitable and inclusive genomic medicine.